Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07526350) titled 'MTS109 in Patients With Refractory Autoimmune Diseases' on April 6.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Changzheng Hospital
Condition:
Systemic Lupus Erythematosus
Idiopathic Inflammatory Myopathies
Systemic Sclerosis (SSc)
ANCA-Associated Vasculitis (AAV)
Sjogren's Syndrome (SS)
Intervention:
Drug: MTS109
Recruitment Status: Recruiting
Phase: Early Phase 1
Date of First Enrollment: March 24, 2026
Target Sample Size: 15
Countries of Recruitment:
China
To...